Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from the long tradition of targeting neurotransmitter systems, but each has a differentiated target profile that could address unserved patients.

It’s also well-positioned to move a third candidate into Phase III, this time with a program that takes the opposite tack, targeting a validated mechanism and differentiating based on selectivity. ...